The afternoon session on “Advancing Analytical Sciences” reached its regulatory compliance zenith as Dr. Pramod Kumar Ragham, Senior Director of Analytical Services at Daicel Chiral Technologies India Pvt Ltd, delivered an authoritative exposition on Extractables & Leachables (E&L) testing that transcended conventional safety protocols to reveal the sophisticated analytical ecosystem underpinning pharmaceutical product integrity. His comprehensive presentation positioned E&L testing not as peripheral quality control but as fundamental pharmaceutical safety architecture requiring unprecedented analytical sophistication and regulatory vigilance.
Beyond Traditional Quality Control
Dr. Ragham’s presentation fundamentally repositioned E&L testing within the pharmaceutical development paradigm, emphasizing that container-closure system interactions represent one of the most underestimated yet critical factors affecting drug product safety and efficacy. His detailed exposition revealed sophisticated analytical workflows that extend far beyond traditional quality control to encompass predictive safety assessment, regulatory compliance strategy, and comprehensive risk evaluation throughout the pharmaceutical product lifecycle.
The integration of E&L testing with broader pharmaceutical development strategies reflects the industry’s recognition that packaging interactions can fundamentally alter drug product characteristics in ways that traditional stability testing may not adequately capture. Dr. Ragham’s emphasis on manufacturing component evaluation alongside primary packaging assessment demonstrates the comprehensive approach required for contemporary pharmaceutical safety assurance.
Regulatory Evolution
Dr. Ragham’s detailed analysis of the evolving regulatory framework revealed the sophisticated compliance environment surrounding E&L testing, with particular emphasis on the proliferation of guidance documents across multiple regulatory jurisdictions. His systematic review of USP chapters including USP-661, USP-663, USP-664, and the recently released USP-664.5 for oral dosage forms demonstrates the expanding scope of E&L requirements beyond traditional parenteral and ophthalmic applications.
The presentation’s emphasis on emerging USP chapters, including the recently commented USP-664.2 and USP-664.5, revealed regulatory agencies’ recognition that E&L considerations extend throughout pharmaceutical dosage forms rather than being limited to sterile products. Dr. Ragham’s discussion of ISO 10993 standards for medical devices demonstrated the parallel evolution of safety requirements across pharmaceutical and medical device industries.
The introduction of ICH Q3E, officially launching in November 2025, represents a paradigmatic shift toward harmonized international E&L standards. Dr. Ragham’s anticipation of this development suggests that pharmaceutical companies must prepare for substantially more rigorous and standardized E&L requirements that will influence global product development strategies.
Precision in Safety Assessment
Dr. Ragham’s detailed exposition of Analytical Evaluation Threshold (AET) calculations revealed sophisticated approaches to risk-based safety assessment that balance analytical sensitivity with practical regulatory compliance. His discussion of safety concern thresholds—0.15 μg/day for Orally Inhaled and Nasal Drug Products (OINDP) and 1.5 μg/day for Parenterally Administered Products (PAP)—demonstrates the regulatory precision required for contemporary E&L assessment.
The presentation’s emphasis on qualification thresholds (5 μg/day) and the complex calculations involving maximum daily doses, uncertainty factors, and surrogate standard considerations revealed the sophisticated risk assessment frameworks underlying modern E&L evaluation. Dr. Ragham’s discussion of the ongoing debate regarding 50% uncertainty factors demonstrates the evolving nature of E&L risk assessment methodologies.
Advanced Analytical Methodologies
Dr. Ragham’s comprehensive review of analytical techniques required for E&L testing revealed the sophisticated instrumental capabilities necessary for detecting compounds at parts-per-billion levels across diverse chemical classes. His systematic categorization of analytical approaches—GC-MS/MS for volatile organic compounds, LC-MS/MS for non-volatile organic compounds, and ICP-MS for elemental impurities—demonstrates the multi-modal analytical strategies required for comprehensive E&L assessment.
The presentation’s emphasis on extending elemental analysis beyond conventional ICH Q3D requirements (24 elements) to encompass 34-37 elements reflects the comprehensive approach required for contemporary E&L evaluation. Dr. Ragham’s discussion of silicon and other non-traditional elemental impurities demonstrates the analytical sophistication required for complete extractables characterization.
The integration of high-resolution mass spectrometry, tandem mass spectrometry, and specialized ionization techniques creates analytical platforms capable of detecting and characterizing previously undetectable packaging-derived impurities. Dr. Ragham’s discussion of fragmentation pattern analysis and database correlation demonstrates the sophisticated identification strategies required for unknown compound characterization.
Manufacturing Component Assessment
Dr. Ragham’s detailed analysis of manufacturing component evaluation revealed sophisticated approaches to identifying potential leachables sources throughout pharmaceutical production processes. His systematic examination of filters, tubing, lubricants, metals, and process equipment demonstrates the comprehensive scope required for modern E&L assessment.
The presentation’s emphasis on process-specific risk assessment, including temperature exposure, contact time, and chemical compatibility evaluation, demonstrates the integration of manufacturing science with analytical chemistry required for effective E&L programs. Dr. Ragham’s discussion of secondary and tertiary packaging evaluation reflects the industry’s recognition that leachables risks extend beyond primary container-closure systems.
Expanding E&L Horizons
Dr. Ragham’s extension of E&L principles to medical device applications revealed sophisticated analytical challenges requiring specialized methodological approaches. His differentiation between direct patient contact devices (catheters, implants, contact lenses) and indirect contact devices (IV infusion sets, ventilator tubing) demonstrates the diverse risk assessment frameworks required for medical device E&L evaluation.
The presentation’s emphasis on patient condition assessment, contact duration, and physiological environment evaluation demonstrates the clinical perspective required for medical device E&L assessment. Dr. Ragham’s discussion of recent FDA guidance on infusion bags and nitrosamine contamination reflects the evolving regulatory attention to medical device leachables safety.
Microsphere Formulations
Dr. Ragham’s detailed analysis of microsphere E&L testing revealed unprecedented analytical challenges requiring sophisticated extraction strategies and multi-modal characterization approaches. His discussion of polymer matrix layers (PLA, PLGA, ethyl cellulose) combined with active drug substances and process-related excipients demonstrates the analytical complexity required for advanced drug delivery system evaluation.
The presentation’s emphasis on multi-solvent extraction strategies reflects the recognition that single extraction approaches cannot adequately characterize complex microsphere formulations. Dr. Ragham’s discussion of regulatory agency expectations for comprehensive microsphere characterization demonstrates the sophisticated analytical requirements for advanced pharmaceutical technologies.
Database Integration & Structure Identification
Dr. Ragham’s systematic approach to unknown compound identification revealed sophisticated database correlation strategies that integrate fragmentation pattern analysis with structural prediction algorithms. His categorization of identification confidence levels—unidentified, partially identified, tentatively identified, and confirmed—demonstrates the nuanced approach required for regulatory-compliant structure elucidation.
The presentation’s emphasis on minimum identification requirements and the distinction between screening-level and quantitative-level identification reflects the practical analytical challenges facing E&L laboratories. Dr. Ragham’s discussion of database limitations and the need for procuring authentic standards when impurities exceed AET demonstrates the comprehensive analytical commitment required for regulatory compliance.
ICH M7 Applications
Dr. Ragham’s integration of E&L testing with ICH M7 mutagenic impurity assessment revealed sophisticated approaches to safety evaluation that extend beyond simple detection to encompass comprehensive toxicological characterization. His discussion of QSAR modeling and expert rule-based systems for toxicity prediction demonstrates the computational approaches required for modern pharmaceutical safety assessment.
The presentation’s emphasis on classification-based control strategies and the integration of toxicological assessment with analytical method development reflects the interdisciplinary approach required for contemporary pharmaceutical safety evaluation.
Industry Implementation
Dr. Ragham’s presentation drew credibility from Daicel Chiral Technologies’ extensive industry experience, including five USFDA audits and comprehensive service capabilities spanning GMP and non-GMP applications. His discussion of global pharmaceutical company partnerships and specialized chiral chemistry expertise provided practical validation for the methodological approaches presented.
The presentation’s emphasis on real-world implementation challenges and regulatory acceptance strategies reflected the perspective of an organization actively navigating complex E&L requirements across diverse pharmaceutical applications.
Dr. Ragham’s anticipation of ICH Q3E implementation and evolving USP guidance documents positioned E&L testing as a rapidly evolving field requiring continuous adaptation and methodological advancement. His discussion of emerging analytical capabilities and expanding regulatory scope suggests that pharmaceutical companies must invest substantially in E&L infrastructure to maintain compliance with evolving requirements.
The presentation’s emphasis on paperless laboratory integration and automated data management reflects the digital transformation occurring within E&L testing laboratories, enabling more sophisticated data analysis and regulatory reporting capabilities.
Dr. Ragham’s comprehensive exposition revealed E&L testing as a strategic pharmaceutical capability rather than a compliance obligation, with significant implications for product development timelines, regulatory approval success, and post-market surveillance requirements. The analytical sophistication required for contemporary E&L testing represents substantial investment in instrumentation, expertise, and methodological development.
The presentation suggested that pharmaceutical companies lacking comprehensive E&L capabilities may face significant competitive disadvantages in regulatory submission success and global market access, particularly as regulatory requirements continue expanding across dosage forms and therapeutic applications.
E&L Testing as Pharmaceutical Safety Foundation
Dr. Pramod Kumar Ragham’s presentation at Analytica Lab India 2025 positioned Extractables & Leachables testing as fundamental pharmaceutical safety architecture requiring unprecedented analytical sophistication, regulatory expertise, and strategic integration with broader pharmaceutical development processes. His comprehensive exposition revealed E&L testing not as peripheral quality control but as essential pharmaceutical science requiring continuous advancement and strategic investment.
The sophisticated methodological approaches, regulatory compliance strategies, and analytical capabilities presented suggest that E&L testing represents one of the most technically demanding aspects of contemporary pharmaceutical development. Organizations that successfully master these capabilities will likely emerge as leaders in pharmaceutical safety and regulatory compliance, while those that underestimate the complexity may face significant challenges in global market access and regulatory acceptance.
As pharmaceutical formulations become increasingly sophisticated and regulatory requirements continue expanding, Dr. Ragham’s presentation suggests that E&L testing will become even more central to pharmaceutical development success, requiring sustained investment in analytical capabilities, regulatory expertise, and technological advancement.
- Naresh Nunna
